International Journal of Clinical Research

Objective To analyze the clinical value of ulinastatin in the treatment of patients with autoimmune liver disease complicated with chronic and acute liver failure. Methods A total of 120 patients with autoimmune liver disease complicated with chronic and acute liver failure received treatment in our hospital were selected and divided into two groups by random number table method: observation group and control group, with 60 patients in each group. The control group received conventional treatment, while the observation group was treated with ulinastatin. The final therapeutic effect of the two groups was analyzed and compared in detail. Results The results of the two groups showed that the improvement time of symptoms in the observation group was shorter than that in the control group, the improvement effect of liver function in the patients was better than that in the control group, and the total effective rate was significantly higher than that in the control group (P < 0.05). Conclusion Adding ulinastatin to the treatment of patients with autoimmune liver disease combined with chronic and acute liver failure can further improve the clinical therapeutic effect, reduce the degree of liver function injury and reduce the harm of the disease.

Autoimmune liver disease; Chronic acute liver failure; Ulinastatin; Value analysis